Physician profile
Joseph Kandel
NPI 1427057462
$9,065.08
in general payments reported to CMS, 2019-2025
32 companies · $1,832 in 2025
The $1,832 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $749 · 2020: $781 · 2021: $1,679 · 2022: $1,099 · 2023: $1,280 · 2024: $1,645 · 2025: $1,832.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,757.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,757.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,083.07 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $1,326.33 | 2019-2025 | Austedo Xr, Austedo, Austedo Xr |
| Pfizer INC. | $788.97 | 2019-2025 | |
| Allergan, INC. | $576.60 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $568.04 | 2020-2021 | |
| Eisai INC. | $490.61 | 2023-2025 | |
| Scilex Pharmaceuticals INC. | $368.80 | 2019-2024 | Ztlido |
| Biohaven Pharmaceutical Holding Company LTD. | $342.93 | 2022 | |
| Acadia Pharmaceuticals INC | $329.00 | 2020-2025 | Nuplazid |
| Lilly USA, LLC | $171.19 | 2021-2025 | Amyvid, Kisunla, Reyvow |
| Merz Pharmaceuticals, LLC | $144.24 | 2024-2025 | Inbrija, Xeomin |
| Horizon Therapeutics Plc | $107.38 | 2019-2021 | |
| Lundbeck LLC | $89.82 | 2024-2025 | Vyepti |
| Amneal Pharmaceuticals LLC | $88.65 | 2019-2025 | Crexont |
| Nevro Corp. | $84.12 | 2019-2024 | Senza |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $74.76 | 2019-2025 | Vumerity, Tysabri |
| Janssen Biotech, INC. | $49.03 | 2025 | |
| Upsher-Smith Laboratories LLC | $45.27 | 2021 | |
| Ucb, INC. | $44.39 | 2023-2024 | Rystiggo |
| Revance Therapeutics, INC. | $44.37 | 2024 | Daxxify |
| Kyowa Kirin, INC. | $26.67 | 2021 | |
| Genentech USA, INC. | $25.76 | 2024 | Evrysdi |
| Abbott Laboratories | $24.14 | 2025 | Infinity |
| Neurocrine Biosciences, INC. | $23.90 | 2022 | |
| Assertio Therapeutics, INC. | $21.77 | 2020 | |
| Acorda Therapeutics, INC | $21.10 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $20.95 | 2025 | Rexulti |
| Novartis Pharmaceuticals Corporation | $18.58 | 2022 | |
| Insightec,INC | $17.77 | 2025 | Exablate |
| Shire North American Group INC | $16.40 | 2019 | |
| Medtronic, INC. | $15.40 | 2025 | Percept PC Brainsense |
| Sunovion Pharmaceuticals INC. | $15.07 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Kandel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.